Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Blood triglycerides increased? 551 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 551 reports of Blood triglycerides increased have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.4% of all adverse event reports for EVOLOCUMAB.

551
Reports of Blood triglycerides increased with EVOLOCUMAB
0.4%
of all EVOLOCUMAB reports
0
Deaths
17
Hospitalizations

How Dangerous Is Blood triglycerides increased From EVOLOCUMAB?

Of the 551 reports, 17 (3.1%) required hospitalization, and 3 (0.5%) were considered life-threatening.

Is Blood triglycerides increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 551 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Blood triglycerides increased?

ISOTRETINOIN (927) ADALIMUMAB (289) ROSUVASTATIN (287) ATORVASTATIN (228) CLOZAPINE (219) OLANZAPINE (219) EVEROLIMUS (215) ICOSAPENT ETHYL (207) METFORMIN (199) TOFACITINIB (198)

Which EVOLOCUMAB Alternatives Have Lower Blood triglycerides increased Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Blood triglycerides increased Reports All Drugs Causing Blood triglycerides increased EVOLOCUMAB Demographics